Karlin Daniel 4

What Happened
Daniel Karlin, Chief Medical Officer of Definium Therapeutics (DFTX), reported the sale of 8,018 common shares on March 25, 2026. The shares were sold at a weighted average price of $18.47 for total proceeds of approximately $148,092. This was a sale (disposition) to satisfy tax withholding obligations related to vested restricted stock units.

Key Details

• Transaction date: March 25, 2026. Filing date: March 26, 2026 (appears timely).
• Price: weighted average $18.47; individual sale prices ranged from $18.36 to $18.80.
• Shares sold: 8,018; total proceeds ≈ $148,092.
• Shares owned after the transaction: not specified in the filing.
• Notable footnotes:
  • F1: Sale to satisfy withholding tax on vested RSUs via sell-to-cover elections under a Rule 10b5-1 plan (plan adopted June 14, 2022).
  • F2: Reported price is weighted average; seller can provide breakdown of shares sold at each price upon request.
  • F3: Filing notes an amount includes 1,586 shares acquired under the 2024 Employee Share Purchase Plan (ESPP).

Context
This was a routine sell-to-cover transaction tied to tax withholding for vested awards, executed under a pre-established 10b5-1 plan. Such transactions are common and generally reflect tax obligations rather than a directional view on the company’s stock.